These efforts have, for instance, revealed that the expression level of the miR-31-3p allows the identification of patients with wild-type KRAS metastatic colorectal cancer responding to anti-EGFR therapy [128]. The gene discussed is EGFR; the disease is metastatic colorectal cancer.